ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has raised an additional CHF 23M (USD 22M, EUR 14M) in an extended Series B venture round. “We are delighted to announce the expansion of our proprietary pipeline with this additional financing. This includes building broad franchises in ophthalmology, rheumatology and […]
Less
More
AqueSys Inc, a company developing a proprietary surgical device for the treatment of glaucoma, has raised a $9 million Series B funding. Glaucoma is the second leading cause of blindness worldwide and affects up to 65 million individuals.
Potentia Pharmaceuticals, Inc., a private development-stage biotechnology company, announced today that it has completed a $12 million round of financing. POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). “Millions of patients are eager for an effective treatment for dry AMD. Complement […]
OptiMedica Corp., a global ophthalmic device company, has announced the receipt of $16 million in Series C financing. OptiMedica holds the exclusive license to the PASCAL® (PAttern SCAn Laser) method of photocoagulation and its associated technologies, which are approved by the U.S. Food and Drug Administration for treatment of a variety of retinal conditions. Clinical […]
Alimera Sciences today announced that it has closed a Series C financing round of $30 million. Alimera Sciences Inc. is singularly focused on the development and commercialization of prescription ophthalmology pharmaceuticals. Alimera completed enrollment in October 2007 of its 956-patient Phase III clinical trial of fluocinolone acetonide in the Medidur(TM) drug delivery system for the […]
I-Therapeutix Inc., a Waltham, Mass.-based developer of situ formed hydrogel therapeutic products for ophthalmology, has raised $6 million in Series B funding. I-Therapeutix is a privately held medical device company that is currently engaged in development of in situ formed hydrogel therapeutic products specifically for ophthalmology. I-Therapeutix, Inc.’s first product, I-Zip is expected to be […]
Oraya Therapeutics Inc., a stealthy medical-device developer in Menlo Park, Calif., raised $4 million in a first funding round. VentureWire says the company is working on some sort of unspecified ophthalmology device.
Paradigm Medical Industries Inc., a Utah provider of glaucoma diagnostic and management devices, said it has completed a $1 million round of funding. A major portion of the proceeds will be used to fund the introduction, marketing and distribution of new ophthalmic instruments and systems this year, the company said. Raymond Cannefax, Paradigm Medical’s chief […]
Sensimed AG, a manufacturer of medical devices in the field of ophthalmology, is receiving CHF8 million ($4.8 mm). Sensimed is a medical device company focusing on the design, development, and commercialization of integrated micro-systems for medical diagnosis and treatment monitoring in the area of ophthalmology. “Our core development product is a first-in-its-category, non-invasive system for […]
Fovea Pharmaceuticals SA has raised EUR 30 million ($43.5 mm) in Series B funding. Fovea Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovation in products for ocular diseases (retinal degeneration, macular edema, glaucoma, and inflammation). Treatments for: Back of the eye diseases, Age related macular degeneration, Retinal degeneration, Dry AMD, […]
Age-related Macular Degeneration
BioTechnology